159 related articles for article (PubMed ID: 37078706)
1. Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study.
Deng LJ; Zhou KS; Liu LH; Zhang MZ; Li ZM; Ji CY; Xu W; Liu T; Xu B; Wang X; Gao SJ; Zhang HL; Hu Y; Li Y; Cheng Y; Yang HY; Cao JN; Zhu ZM; Hu JD; Zhang W; Jing HM; Ding KY; Zhang XY; Zhao RB; Zhang B; Tian YM; Song YP; Song YQ; Zhu J
Blood Adv; 2023 Aug; 7(16):4349-4357. PubMed ID: 37078706
[TBL] [Abstract][Full Text] [Related]
2. Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study.
Song Y; Zhou K; Zou D; Zhou J; Hu J; Yang H; Zhang H; Ji J; Xu W; Jin J; Lv F; Feng R; Gao S; Guo H; Zhou L; Huang J; Novotny W; Kim P; Yu Y; Wu B; Zhu J
Blood; 2022 May; 139(21):3148-3158. PubMed ID: 35303070
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.
Wang ML; Blum KA; Martin P; Goy A; Auer R; Kahl BS; Jurczak W; Advani RH; Romaguera JE; Williams ME; Barrientos JC; Chmielowska E; Radford J; Stilgenbauer S; Dreyling M; Jedrzejczak WW; Johnson P; Spurgeon SE; Zhang L; Baher L; Cheng M; Lee D; Beaupre DM; Rule S
Blood; 2015 Aug; 126(6):739-45. PubMed ID: 26059948
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase.
Song Y; Zhou K; Zou D; Zhou J; Hu J; Yang H; Zhang H; Ji J; Xu W; Jin J; Lv F; Feng R; Gao S; Guo H; Zhou L; Elstrom R; Huang J; Novotny W; Wei R; Zhu J
Clin Cancer Res; 2020 Aug; 26(16):4216-4224. PubMed ID: 32461234
[TBL] [Abstract][Full Text] [Related]
5. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study.
Xu W; Yang S; Zhou K; Pan L; Li Z; Zhou J; Gao S; Zhou D; Hu J; Feng R; Huang H; Ji M; Guo H; Huang J; Novotny W; Feng S; Li J
J Hematol Oncol; 2020 May; 13(1):48. PubMed ID: 32393328
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of orelabrutinib monotherapy in patients with relapsed or refractory Waldenström's macroglobulinemia in a single-arm, multicenter, open-label, phase 2 study.
Cao XX; Jin J; Fu CC; Yi SH; Zhao WL; Sun ZM; Yang W; Li DJ; Cui GH; Hu JD; Liu T; Song YP; Xu B; Zhu ZM; Xu W; Zhang MZ; Tian YM; Zhang B; Zhao RB; Zhou DB
EClinicalMedicine; 2022 Oct; 52():101682. PubMed ID: 36313145
[TBL] [Abstract][Full Text] [Related]
7. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
Wang ML; Rule S; Martin P; Goy A; Auer R; Kahl BS; Jurczak W; Advani RH; Romaguera JE; Williams ME; Barrientos JC; Chmielowska E; Radford J; Stilgenbauer S; Dreyling M; Jedrzejczak WW; Johnson P; Spurgeon SE; Li L; Zhang L; Newberry K; Ou Z; Cheng N; Fang B; McGreivy J; Clow F; Buggy JJ; Chang BY; Beaupre DM; Kunkel LA; Blum KA
N Engl J Med; 2013 Aug; 369(6):507-16. PubMed ID: 23782157
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma.
Maruyama D; Nagai H; Fukuhara N; Kitano T; Ishikawa T; Shibayama H; Choi I; Hatake K; Uchida T; Nishikori M; Kinoshita T; Matsuno Y; Nishikawa T; Takahara S; Tobinai K
Cancer Sci; 2016 Dec; 107(12):1785-1790. PubMed ID: 27616553
[TBL] [Abstract][Full Text] [Related]
9. Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma.
Wang ML; Jurczak W; Zinzani PL; Eyre TA; Cheah CY; Ujjani CS; Koh Y; Izutsu K; Gerson JN; Flinn I; Tessoulin B; Alencar AJ; Ma S; Lewis D; Lech-Maranda E; Rhodes J; Patel K; Maddocks K; Lamanna N; Wang Y; Tam CS; Munir T; Nagai H; Hernandez-Ilizaliturri F; Kumar A; Fenske TS; Seymour JF; Zelenetz AD; Nair B; Tsai DE; Balbas M; Walgren RA; Abada P; Wang C; Zhao J; Mato AR; Shah NN
J Clin Oncol; 2023 Aug; 41(24):3988-3997. PubMed ID: 37192437
[TBL] [Abstract][Full Text] [Related]
10. Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study.
Deng L; Li Z; Zhang H; Huang H; Hu J; Liu L; Liu T; Jin J; Zhu Z; Li W; Huang Z; Huang W; Zhou K; Yang H; Zhang M; Ding K; Zhou H; Hu Y; Shuang Y; Cao J; Gao S; Li D; Sun Z; Zhang Q; Yi S; Ji C; Zhang L; Hou C; Du Y; Wang W; Zhao R; Song Y; Zhu J
Am J Hematol; 2023 Nov; 98(11):1742-1750. PubMed ID: 37647123
[TBL] [Abstract][Full Text] [Related]
11. Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.
Trněný M; Lamy T; Walewski J; Belada D; Mayer J; Radford J; Jurczak W; Morschhauser F; Alexeeva J; Rule S; Afanasyev B; Kaplanov K; Thyss A; Kuzmin A; Voloshin S; Kuliczkowski K; Giza A; Milpied N; Stelitano C; Marks R; Trümper L; Biyukov T; Patturajan M; Bravo MC; Arcaini L;
Lancet Oncol; 2016 Mar; 17(3):319-331. PubMed ID: 26899778
[TBL] [Abstract][Full Text] [Related]
12. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.
Wang M; Rule S; Zinzani PL; Goy A; Casasnovas O; Smith SD; Damaj G; Doorduijn J; Lamy T; Morschhauser F; Panizo C; Shah B; Davies A; Eek R; Dupuis J; Jacobsen E; Kater AP; Le Gouill S; Oberic L; Robak T; Covey T; Dua R; Hamdy A; Huang X; Izumi R; Patel P; Rothbaum W; Slatter JG; Jurczak W
Lancet; 2018 Feb; 391(10121):659-667. PubMed ID: 29241979
[TBL] [Abstract][Full Text] [Related]
13. A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies.
Walter HS; Rule SA; Dyer MJ; Karlin L; Jones C; Cazin B; Quittet P; Shah N; Hutchinson CV; Honda H; Duffy K; Birkett J; Jamieson V; Courtenay-Luck N; Yoshizawa T; Sharpe J; Ohno T; Abe S; Nishimura A; Cartron G; Morschhauser F; Fegan C; Salles G
Blood; 2016 Jan; 127(4):411-9. PubMed ID: 26542378
[TBL] [Abstract][Full Text] [Related]
14. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
Mato AR; Shah NN; Jurczak W; Cheah CY; Pagel JM; Woyach JA; Fakhri B; Eyre TA; Lamanna N; Patel MR; Alencar A; Lech-Maranda E; Wierda WG; Coombs CC; Gerson JN; Ghia P; Le Gouill S; Lewis DJ; Sundaram S; Cohen JB; Flinn IW; Tam CS; Barve MA; Kuss B; Taylor J; Abdel-Wahab O; Schuster SJ; Palomba ML; Lewis KL; Roeker LE; Davids MS; Tan XN; Fenske TS; Wallin J; Tsai DE; Ku NC; Zhu E; Chen J; Yin M; Nair B; Ebata K; Marella N; Brown JR; Wang M
Lancet; 2021 Mar; 397(10277):892-901. PubMed ID: 33676628
[TBL] [Abstract][Full Text] [Related]
15. Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma.
Tam CS; Opat S; Simpson D; Cull G; Munoz J; Phillips TJ; Kim WS; Rule S; Atwal SK; Wei R; Novotny W; Huang J; Wang M; Trotman J
Blood Adv; 2021 Jun; 5(12):2577-2585. PubMed ID: 34152395
[TBL] [Abstract][Full Text] [Related]
16. Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.
Burris HA; Flinn IW; Patel MR; Fenske TS; Deng C; Brander DM; Gutierrez M; Essell JH; Kuhn JG; Miskin HP; Sportelli P; Weiss MS; Vakkalanka S; Savona MR; O'Connor OA
Lancet Oncol; 2018 Apr; 19(4):486-496. PubMed ID: 29475723
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial.
Wang M; Fayad L; Wagner-Bartak N; Zhang L; Hagemeister F; Neelapu SS; Samaniego F; McLaughlin P; Fanale M; Younes A; Cabanillas F; Fowler N; Newberry KJ; Sun L; Young KH; Champlin R; Kwak L; Feng L; Badillo M; Bejarano M; Hartig K; Chen W; Chen Y; Byrne C; Bell N; Zeldis J; Romaguera J
Lancet Oncol; 2012 Jul; 13(7):716-23. PubMed ID: 22677155
[TBL] [Abstract][Full Text] [Related]
18. Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.
Diefenbach C; Kahl BS; McMillan A; Briones J; Banerjee L; Cordoba R; Miall F; Burke JM; Hirata J; Jiang Y; Paulson JN; Chang YM; Musick L; Abrisqueta P
Lancet Haematol; 2021 Dec; 8(12):e891-e901. PubMed ID: 34826412
[TBL] [Abstract][Full Text] [Related]
19. A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma.
Strati P; Coleman M; Champion R; Ma S; Patti C; Levy MY; Lossos IS; Geethakumari PR; Lam S; Calvo R; Higgins K; Budde LE
Br J Haematol; 2022 Oct; 199(1):76-85. PubMed ID: 35861370
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma.
Habermann TM; Lossos IS; Justice G; Vose JM; Wiernik PH; McBride K; Wride K; Ervin-Haynes A; Takeshita K; Pietronigro D; Zeldis JB; Tuscano JM
Br J Haematol; 2009 May; 145(3):344-9. PubMed ID: 19245430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
